Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124637902 | 12463790 | 2 | F | 200601 | 20160630 | 20160614 | 20160708 | EXP | US-ASTRAZENECA-2008BM04407 | ASTRAZENECA | 661.00 | MON | F | Y | 76.70000 | KG | 20160708 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124637902 | 12463790 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | 0.25 MG/ML, 5 MICROGRAMS TWO TIMES A DAY | Y | U | 9RY64M | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||
| 124637902 | 12463790 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | 0.25 MG/ML, 10 MICROGRAMS TWO TIMES A DAY | Y | U | 9RY64M | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||
| 124637902 | 12463790 | 3 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | 10 | Y | U | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||||
| 124637902 | 12463790 | 4 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | SDT, 2 MILLIGRAMS PER WEEK | 22200 | ||||||||||
| 124637902 | 12463790 | 5 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | PEN, 2 MILLIGRAMS PER WEEK | 22200 | ||||||||||
| 124637902 | 12463790 | 6 | C | AVANDIA | ROSIGLITAZONE MALEATE | 1 | EVERY DAY | 0 | |||||||||||
| 124637902 | 12463790 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 2000 | MG | QD | ||||||||
| 124637902 | 12463790 | 8 | C | GLIMIPIRIDE | GLIMEPIRIDE | 1 | Oral | 0 | 2 | MG | QD | ||||||||
| 124637902 | 12463790 | 9 | C | NORTRIPTYLINE | NORTRIPTYLINE | 1 | Oral | 25.0MG UNKNOWN | 0 | 25 | MG | ||||||||
| 124637902 | 12463790 | 10 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MILLIGRAMS | 0 | ||||||||||
| 124637902 | 12463790 | 11 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | TWO TIMES A DAY | 0 | ||||||||||
| 124637902 | 12463790 | 12 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 124637902 | 12463790 | 13 | C | INVOKANA | CANAGLIFLOZIN | 1 | Oral | 0 | 300 | MG | QD | ||||||||
| 124637902 | 12463790 | 14 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | QD | ||||||||
| 124637902 | 12463790 | 15 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 0 | 3.125 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124637902 | 12463790 | 1 | Type 2 diabetes mellitus |
| 124637902 | 12463790 | 2 | Type 2 diabetes mellitus |
| 124637902 | 12463790 | 3 | Type 2 diabetes mellitus |
| 124637902 | 12463790 | 4 | Type 2 diabetes mellitus |
| 124637902 | 12463790 | 5 | Type 2 diabetes mellitus |
| 124637902 | 12463790 | 6 | Type 2 diabetes mellitus |
| 124637902 | 12463790 | 7 | Diabetes mellitus |
| 124637902 | 12463790 | 8 | Diabetes mellitus |
| 124637902 | 12463790 | 9 | Depression |
| 124637902 | 12463790 | 10 | Neuropathy peripheral |
| 124637902 | 12463790 | 11 | Neuropathy peripheral |
| 124637902 | 12463790 | 12 | Blood cholesterol increased |
| 124637902 | 12463790 | 13 | Diabetes mellitus |
| 124637902 | 12463790 | 14 | Cerebrovascular accident |
| 124637902 | 12463790 | 15 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124637902 | 12463790 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124637902 | 12463790 | Abdominal distension | |
| 124637902 | 12463790 | Blood glucose decreased | |
| 124637902 | 12463790 | Cerebrovascular accident | |
| 124637902 | 12463790 | Device malfunction | |
| 124637902 | 12463790 | Extra dose administered | |
| 124637902 | 12463790 | Incorrect dose administered | |
| 124637902 | 12463790 | Injection site bruising | |
| 124637902 | 12463790 | Injection site extravasation | |
| 124637902 | 12463790 | Injection site haemorrhage | |
| 124637902 | 12463790 | Injection site mass | |
| 124637902 | 12463790 | Injection site pain | |
| 124637902 | 12463790 | Injection site urticaria | |
| 124637902 | 12463790 | Injury associated with device | |
| 124637902 | 12463790 | Tinnitus | |
| 124637902 | 12463790 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124637902 | 12463790 | 1 | 20051213 | 20060112 | 0 | |
| 124637902 | 12463790 | 2 | 20060113 | 0 | ||
| 124637902 | 12463790 | 3 | 2005 | 2014 | 0 | |
| 124637902 | 12463790 | 4 | 2014 | 201603 | 0 | |
| 124637902 | 12463790 | 5 | 201603 | 0 | ||
| 124637902 | 12463790 | 9 | 1987 | 0 | ||
| 124637902 | 12463790 | 10 | 2002 | 0 | ||
| 124637902 | 12463790 | 11 | 2002 | 0 | ||
| 124637902 | 12463790 | 12 | 201601 | 0 |